The predictive value of PD-L1 expression and tumor mutational burden (TMB) mainly focuse on PD-1 and/or PD-L1 monotherapy.7 Notably, both PD-L1 expression8 and TMB9 has limited predictive value for the efficacy of combined chemotherapy and immunotherapy. Here, CD274 is linked to neoplasm.